HIGH-VOLUME · FEMALE-LED

leflunomide Side Effects

leflunomide (also sold as Arava) is HIGH-VOLUME in this FAERS book #77 of 524 by FAERS report count. Signature opener: FEMALE-LED - 82% of sex-coded reports are female (74,653 F / 16,529 M).

Data updated 2026-05-15

102,095
FAERS reports

FAERS voluntary reports, 2004 to 2025. High volume tracks exposure and reporting culture; see methodology for de-dup rules.

leflunomide reporting skew - 82% of sex-coded reports are female (74,653 F / 16,529 M). Volume band HIGH-VOLUME #77 of 524 by FAERS report count; caseload MEGA-CASE.

High-report extract for leflunomide (Arava): 102,095 FAERS rows (2004-2025). Top named reactions: RHEUMATOID ARTHRITIS, PAIN, ARTHRALGIA. Outcome stamps DEATH-HEAVY · HOSP-MID · FEMALE-LED. FAERS is voluntary signal detection, not incidence.

Counts from the openFDA FAERS extract (2004–2025). Stamps MEGA-CASE · DEATH-HEAVY · HOSP-MID · FEMALE-LED.

RHEUMATOID ARTHRITIS leads 24,923 of 102,095 reports

RHEUMATOID ARTHRITIS
24,923
PAIN
20,055
ARTHRALGIA
16,941
JOINT SWELLING
15,567
FATIGUE
15,384
RASH
13,321
ABDOMINAL DISCOMFORT
11,731
ALOPECIA
11,692
CONTRAINDICATED PRODUCT ADMINISTERED
11,637
ARTHROPATHY
10,791
CONDITION AGGRAVATED
10,367
SWELLING
10,250
NAUSEA
10,126
SYNOVITIS
10,026
SYSTEMIC LUPUS ERYTHEMATOSUS
9,625
TREATMENT FAILURE
9,615
DRUG HYPERSENSITIVITY
9,588

FEMALE-LED reporters · age peak 45-64

Female-led reporters (82% of sex-coded rows)

Female 74,653 (82%)
Male 16,529 (18%)
Unknown 141

Age peak 45-64 (29,335 reports)

0-17 912 (1%)
18-44 14,295 (23%)
45-64 29,335 (48%)
65-74 11,490 (19%)
75+ 5,158 (8%)

FAERS filings rising toward 2025

2004 2025

Reactions in Death Reports

Death-mentioned subset is HEAVY here (8,456 reports, 8.3%). Top co-reported reactions in that subset - voluntary, not causal.

Reaction Reports
RHEUMATOID ARTHRITIS 2,231
SYSTEMIC LUPUS ERYTHEMATOSUS 2,196
GENERAL PHYSICAL HEALTH DETERIORATION 2,146
GLOSSODYNIA 2,120
TYPE 2 DIABETES MELLITUS 2,093
RASH 2,072
JOINT SWELLING 2,064
HAND DEFORMITY 2,063
FATIGUE 2,058
PSORIATIC ARTHROPATHY 2,051
SYNOVITIS 2,040
DUODENAL ULCER PERFORATION 2,017
HYPOAESTHESIA 2,017
FIBROMYALGIA 2,013
INFUSION RELATED REACTION 1,993
HEPATIC ENZYME INCREASED 1,990
HYPERTENSION 1,985
SWELLING 1,983
HELICOBACTER INFECTION 1,976

Reactions in Hospitalization Reports

Hospitalization mid-share (27,652, 27.1%). Co-reported reactions:

Reaction Reports
RHEUMATOID ARTHRITIS 6,005
PAIN 5,662
ARTHRALGIA 5,457
FATIGUE 4,987
RASH 4,745
JOINT SWELLING 4,576
ARTHROPATHY 4,339
DRUG HYPERSENSITIVITY 4,027
SYNOVITIS 3,959
CONDITION AGGRAVATED 3,941
NAUSEA 3,826
ABDOMINAL DISCOMFORT 3,823
DIARRHOEA 3,729
HEADACHE 3,715
HYPERSENSITIVITY 3,657
INFUSION RELATED REACTION 3,604
VOMITING 3,534
How to read leflunomide FAERS figures (MEGA-CASE · DEATH-HEAVY · HOSP-MID)

FAERS holds 102,095 voluntary reports linked to leflunomide (Arava), 2004-2025. Death is listed on 8,456 (8.3%). Hospitalization appears on 27,652 (27.1%). Top co-reported indication: Rheumatoid Arthritis.

MEGA-CASE books overweight common drugs and loud reporting cultures; FEMALE-LED is the page opener, not a per-patient risk.

Read with leflunomide

Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-MID stamps.